Developer docs
API playgroundTry for free, no card

Search company profiles

SABI Mind

Full company profile

uuid0004bj3

Namestring
SABI Mind
Legal namestring
SABI MIND INC.
Websiteurl
sabimind.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

SABI Mind Inc. is a Calgary, Alberta-based private healthcare company operating psychedelic-assisted therapy clinics for treatment-resistant mental health and chronic pain conditions. Founded in March 2022, the company runs two healing centres — its Calgary flagship in Sunalta and a second location in Victoria, British Columbia opened in April 2024 — delivering a three-phase care model (Preparation, Discovery, Integration) anchored on intramuscular and intravenous ketamine administration and the proprietary ExoMind™ neuromodulation platform built on patented ExoTMS™ repetitive transcranial magnetic stimulation technology, which is Health Canada-cleared for depression.

The company's core products are SABI Therapy for Mental Health and SABI Therapy for Chronic Pain (STCP), both ketamine-led interdisciplinary programs, supplemented by ExoMind™ rTMS therapy, SABI Somatics (body-centered modalities including osteopathic manual therapy, somatic experiencing, and somatic therapy), and dedicated first-responder services under the Beyond The Call sub-brand with a fully covered EXOMIND Support Initiative. SABI Mind also conducts clinical research, including a Health Canada-authorized PsilWell wellness-focused psilocybin therapy trial launched in October 2025 in partnership with TheraPsil, CRIO, and Filament Health, and an earlier Clairvoyant Therapeutics-sponsored alcohol use disorder study. Regulatory credentials include provisional Non-Hospital Surgical Facility (NHSF) accreditation from the College of Physicians and Surgeons of Alberta (November 2024), making SABI Mind the first non-hospital provider of IV ketamine therapy in Alberta.

The revenue model is primarily transactional and per-treatment: program packages priced in the low-thousands CAD range (PsilWell trial at CAD 4,500), with referral discounts, insurance-adjusted pricing, and first-responder subsidies layered on. Customers are predominantly individual patients — mental health sufferers, chronic pain patients, and first responders — acquired through a sales-led, content- and event-driven go-to-market leveraging social media, podcasts, webinars, blog content, and industry conferences. SABI Mind holds trademarked proprietary technology (ExoMind™, ExoTMS™), partnerships with multiple psychedelic compound suppliers (PharmAla, Optimi Health, Filament Health), and operates under Health Canada special access program approvals. As of May 2023, the company had raised only approximately $180,365 USD via an SEC Regulation D offering, indicating a founder-led capital structure rather than institutional-backed scaling.

Short descriptiontext

SABI Mind operates two Canadian psychedelic-assisted therapy clinics in Calgary and Victoria, delivering ketamine and ExoMind rTMS treatments for treatment-resistant mental health and chronic pain conditions, with specialized first-responder programs and active clinical trial participation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCalgary, Canada
HQ citystring
Calgary
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ketamine therapy, psychedelic assisted therapy, chronic pain treatment, transcranial magnetic stimulation, mental health clinic
Industry2 codes
PRIMARYHLAFABAC
Outpatient Mental Health & Counseling Clinics
Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers
SECONDARYHLADAJAG
Multidisciplinary Outpatient Rehab Centers (PT/OT/SLP)
Healthcare & Life Sciences/Elder Care & Long-Term Care/Rehabilitation & Post-Acute Care Centers (Inpatient/Outpatient)
NAICS code3 codes
  • Outpatient Mental Health and Substance Abuse Centers621420
  • Offices of Physicians, Mental Health Specialists621112
  • Offices of Mental Health Practitioners (except Physicians)621330
SIC code2 codes
  • Services-Specialty Outpatient Facilities, Nec8093
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Mental Health & Chronic Pain Treatment Services
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Therapeutic Treatment Services
TypeOne Time License
Description

Revenue generated from administering psychedelic-assisted therapies including ketamine treatments, psilocybin therapy, and MDMA-assisted therapy programs. Treatment programs are priced as comprehensive packages including screening, therapy sessions, and follow-up care.

2Clinical Research Services
TypeProfessional Services
Description

Revenue from conducting clinical trials including the PsilWell trial, providing therapeutic services to research participants under Health Canada approvals.

3EXOMIND Support Programs
TypeSubscription Recurring
Description

Specialized brain health and mental wellness programs offered through the Beyond The Call initiative for first responders, with discounted pricing for program access.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details4 tiers
1PsilWell Clinical Trial - CAD 4,500
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Complete program cost covering all screening, ketamine-assisted therapy sessions, and follow-up care for eligible participants

2EXOMIND Support Initiative - 20% first responder discount
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Discounted pricing on EXOMIND programs for first responders participating in the Beyond The Call initiative

3Ketamine Therapy Sessions - 25% referral discount
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Referral program offering 25% discount on ketamine therapy sessions for patients who refer others

4Insurance-adjusted pricing - 10% reduction
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Reduced pricing option offering 10% discount when insurance coverage is not available

GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 5 records shown
1EXOMIND
Description

A groundbreaking mental wellness therapy using patented ExoTMS technology for repetitive transcranial magnetic stimulation (rTMS) to treat symptoms of depression and improve mental health.

sabimind.com
+4 more records
Core offering1 text field

SABI Mind operates clinical healing centres in Calgary and Victoria, BC, delivering ketamine-assisted psychotherapy, psilocybin-assisted therapy, MDMA-assisted therapy, and ExoMind™ repetitive transcranial magnetic stimulation (rTMS) to patients with treatment-resistant mental health conditions and chronic pain. Treatments follow a three-phase model of Preparation, Discovery, and Integration, with on-site physicians, anesthesiologists, and psychiatrists administering care under Health Canada approvals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • PsilWell clinical trial: CAD 4,500 per participant program
Product overview1 text field

SABI Mind is a psychedelic-assisted therapy clinic offering ketamine and rTMS treatments across two Canadian locations (Calgary and Victoria, BC). The core offerings include SABI Therapy for Mental Health and Chronic Pain (using ketamine), and EXOMIND™ (using patented ExoTMS™ rTMS technology). The company provides a three-phase healing approach: Preparation, Discovery, and Integration. Additional services include SABI Somatics (body-centered therapies), counselling, and manual therapy. Beyond The Call is a specialized sub-brand offering mental health services for first responders with reduced pricing. The company also conducts clinical research including psilocybin trials and maintains NHSF accreditation for IV ketamine administration.

Product and service11 records
1SABI Therapy for Mental Health
CategoryKetamine-Assisted Psychotherapy
Description

Ketamine-assisted psychotherapy administered intramuscularly by qualified physicians, combined with preparation, discovery, and integration phases for individuals with treatment-resistant depression, PTSD, anxiety, and related mental health conditions.

2SABI Therapy for Chronic Pain (STCP)
CategoryChronic Pain Treatment
Description

Interdisciplinary chronic pain program led by chronic pain specialists, using ketamine-assisted therapy combined with integrative therapies for chronic pain conditions.

3EXOMIND™
CategoryTranscranial Magnetic Stimulation
Description

Non-invasive, drug-free neuromodulation therapy using patented ExoTMS™ repetitive transcranial magnetic stimulation (rTMS) technology, Health Canada-cleared for the treatment of depression.

4Beyond The Call
CategorySpecialty Mental Health Program
Description

Dedicated mental health platform for first responders (police, firefighters, paramedics) offering EXOMIND therapy, ketamine therapy, and counselling services with reduced pricing and the EXOMIND Support Initiative providing fully covered treatments for eligible first responders.

5SABI Somatics
CategoryBody-Centered Therapy
Description

Body-centered mental health service stream offering osteopathic manual therapy, somatic therapy, and somatic experiencing coaching for trauma and nervous system regulation.

6Intravenous (IV) Ketamine Therapy
CategoryKetamine Therapy
Description

Intravenous ketamine therapy for treatment-resistant mental health conditions and chronic pain, enabled by provisional Non-Hospital Surgical Facility (NHSF) accreditation from the College of Physicians and Surgeons of Alberta.

7PsilWell Wellness-Focused Psilocybin Therapy Trial
CategoryClinical Trial / Psilocybin Therapy
Description

Wellness-focused psilocybin therapy clinical trial program offering screening, psilocybin-assisted group therapy, and follow-up care for adults aged 18-65, operated in Victoria under Health Canada authorization.

8Equitable Access Program (EAP)
CategoryAccess Program
Description

Access program providing chronic pain and mental health care to historically underserved, underrepresented, or low-income patient populations at reduced or subsidized pricing.

9Psychedelic-Assisted Therapy (PAT)
CategoryPsychedelic-Assisted Therapy
Description

Therapeutic technique using psychedelic substances administered in low to moderate doses under supervision of trained medical and mental health professionals, available at the Victoria location.

10Therapy & Counselling
CategoryCounselling and Psychotherapy
Description

Evidence-based therapeutic approaches tailored to individual client needs for anxiety, depression, relationship issues, and life transitions, delivered as part of the Preparation and Integration phases.

11Manual Therapy
CategoryManual Therapy
Description

Hands-on manual therapy techniques including osteopathy to manipulate and mobilize muscles and joints, alleviate pain, enhance mobility, and release trauma stored in the body.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-06-01
Description

Supply partnership for psilocybin and MDMA therapeutic substances used in clinical trials and treatment programs. Optimi Health provides naturally-sourced psychedelic compounds for therapeutic applications.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-06-01
Description

Psilocybin supply agreement ensuring availability of pharmaceutical-grade psilocybin for clinical research and patient treatment programs.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-05-01
Description

MDMA supply agreement providing pharmaceutical-grade MDMA for clinical research and therapeutic applications. PharmAla Biotech is a Canadian company specializing in psychoactive compound manufacturing for clinical use.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-01
Description

Research partnership focused on advancing psychedelic-assisted therapy protocols and clinical research initiatives for mental health treatments.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership supporting the PsilWell clinical trial, involving collaboration on psilocybin-assisted therapy research for treatment-resistant conditions.

6Beyond The Call
Strategic tierFlagshipTypeGTM or Marketing Partner
Description

EXOMIND Support Initiative partnership providing specialized mental health programs for first responders including police, firefighters, and paramedics, with 20% discounted pricing on programs.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Field Trip Health & Wellness
TypeDirect peer
Description

Field Trip Health & Wellness operates psychedelic-assisted therapy clinics across Canada and the US, directly competing with SABI Mind in ketamine and psilocybin-based mental-health treatment in the same patient segment.

TypeDirect peer
Description

Numinus runs ketamine-assisted therapy clinics in Canada (including British Columbia) and operates a psychedelic research division, overlapping directly with SABI Mind on clinic-based psychedelic therapy in Western Canada.

3ATMA Journey Centers
TypeDirect peer
Description

ATMA operates psychedelic-assisted therapy clinics in Western Canada focused on personal-growth and mental-health programs, competing for the same treatment-resistant patient base as SABI Mind's Calgary and Victoria clinics.

TypeEmerging player
Description

TheraPsil is a Canadian non-profit that runs psilocybin-assisted therapy programs and is an active research partner of SABI Mind (PsilWell trial); its clinical and training activities overlap with SABI Mind's psychedelic therapy offerings.

TypeEmerging player
Description

Clairvoyant Therapeutics is a Canadian clinical-stage psychedelic company running psilocybin trials for alcohol use disorder, of which SABI Mind is the first Alberta clinical site — making it an immediate sponsor/customer peer.

6MindMed
TypeBroad incumbent
Description

MindMed is a publicly-traded psychedelic-medicine developer with clinical programs in mental health and a broader, drug-development-focused footprint than SABI Mind's clinical-services business — overlapping at the patient/indication level.

TypeBroad incumbent
Description

BrainsWay manufactures FDA-cleared deep TMS systems used for depression and OCD treatment; SABI Mind's ExoTMS™/ExoMind™ TMS offerings compete for the same clinical indication and provider-customer relationships.

8Revive Therapeutics
TypeEmerging player
Description

Revive Therapeutics is a Canadian specialty psychedelics company focused on psilocybin therapeutics, positioning it as an adjacent player in the same psilocybin clinical-research ecosystem in which SABI Mind participates.

TypeEmerging player
Description

Mycotopia Therapies provides psilocybin-based mental-health treatment programs in partnership with Canadian clinics; it competes for the same niche Canadian psilocybin-assisted therapy market as SABI Mind.

TypeBroad incumbent
Description

Cerebral is a large US digital mental-health provider offering telehealth therapy and medication management — a much broader, incumbent mental-health-services operator competing for the same downstream treatment-resistant depression patient demand that SABI Mind addresses.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SABI Mind

Mental Health & Chronic Pain Treatment Servicessabimind.com

SABI Mind operates two Canadian psychedelic-assisted therapy clinics in Calgary and Victoria, delivering ketamine and ExoMind rTMS treatments for treatment-resistant mental health and chronic pain conditions, with specialized first-responder programs and active clinical trial participation.

What SABI Mind does

SABI Mind Inc. is a Calgary, Alberta-based private healthcare company operating psychedelic-assisted therapy clinics for treatment-resistant mental health and chronic pain conditions. Founded in March 2022, the company runs two healing centres — its Calgary flagship in Sunalta and a second location in Victoria, British Columbia opened in April 2024 — delivering a three-phase care model (Preparation, Discovery, Integration) anchored on intramuscular and intravenous ketamine administration and the proprietary ExoMind™ neuromodulation platform built on patented ExoTMS™ repetitive transcranial magnetic stimulation technology, which is Health Canada-cleared for depression.

The company's core products are SABI Therapy for Mental Health and SABI Therapy for Chronic Pain (STCP), both ketamine-led interdisciplinary programs, supplemented by ExoMind™ rTMS therapy, SABI Somatics (body-centered modalities including osteopathic manual therapy, somatic experiencing, and somatic therapy), and dedicated first-responder services under the Beyond The Call sub-brand with a fully covered EXOMIND Support Initiative. SABI Mind also conducts clinical research, including a Health Canada-authorized PsilWell wellness-focused psilocybin therapy trial launched in October 2025 in partnership with TheraPsil, CRIO, and Filament Health, and an earlier Clairvoyant Therapeutics-sponsored alcohol use disorder study. Regulatory credentials include provisional Non-Hospital Surgical Facility (NHSF) accreditation from the College of Physicians and Surgeons of Alberta (November 2024), making SABI Mind the first non-hospital provider of IV ketamine therapy in Alberta.

The revenue model is primarily transactional and per-treatment: program packages priced in the low-thousands CAD range (PsilWell trial at CAD 4,500), with referral discounts, insurance-adjusted pricing, and first-responder subsidies layered on. Customers are predominantly individual patients — mental health sufferers, chronic pain patients, and first responders — acquired through a sales-led, content- and event-driven go-to-market leveraging social media, podcasts, webinars, blog content, and industry conferences. SABI Mind holds trademarked proprietary technology (ExoMind™, ExoTMS™), partnerships with multiple psychedelic compound suppliers (PharmAla, Optimi Health, Filament Health), and operates under Health Canada special access program approvals. As of May 2023, the company had raised only approximately $180,365 USD via an SEC Regulation D offering, indicating a founder-led capital structure rather than institutional-backed scaling.

SABI Mind firmographics

Firmographics
Name
SABI Mind
Legal name
SABI MIND INC.
Website
https://sabimind.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
SABI Mind operates two Canadian psychedelic-assisted therapy clinics in Calgary and Victoria, delivering ketamine and ExoMind rTMS treatments for treatment-resistant mental health and chronic pain conditions, with specialized first-responder programs and active clinical trial participation.
Ownership category
akta.pro rank

SABI Mind industry classification

Industry
Product category
Mental Health & Chronic Pain Treatment Services
NAICS
Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112), Offices of Mental Health Practitioners (except Physicians) (621330)
SIC
Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLAFABAC
Outpatient Mental Health & Counseling Clinics
Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers
SECONDARYHLADAJAG
Multidisciplinary Outpatient Rehab Centers (PT/OT/SLP)
Healthcare & Life Sciences/Elder Care & Long-Term Care/Rehabilitation & Post-Acute Care Centers (Inpatient/Outpatient)

Keywords

  • Ketamine therapy
  • Psychedelic assisted therapy
  • Chronic pain treatment
  • Transcranial magnetic stimulation
  • Mental health clinic

Where SABI Mind is headquartered

Location

Headquarters

HQ city
Calgary
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

SABI Mind business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Therapeutic Treatment Services: Revenue generated from administering psychedelic-assisted therapies including ketamine treatments, psilocybin therapy, and MDMA-assisted therapy programs. Treatment programs are priced as comprehensive packages including screening, therapy sessions, and follow-up care.
  2. Clinical Research Services: Revenue from conducting clinical trials including the PsilWell trial, providing therapeutic services to research participants under Health Canada approvals.
  3. EXOMIND Support Programs: Specialized brain health and mental wellness programs offered through the Beyond The Call initiative for first responders, with discounted pricing for program access.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goPsilWell Clinical Trial - CAD 4,500
Unit PricingPay-as-you-goEXOMIND Support Initiative - 20% first responder discount
Unit PricingPay-as-you-goKetamine Therapy Sessions - 25% referral discount
Unit PricingPay-as-you-goInsurance-adjusted pricing - 10% reduction

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

SABI Mind product offering

Product offering

Core offering

SABI Mind operates clinical healing centres in Calgary and Victoria, BC, delivering ketamine-assisted psychotherapy, psilocybin-assisted therapy, MDMA-assisted therapy, and ExoMind™ repetitive transcranial magnetic stimulation (rTMS) to patients with treatment-resistant mental health conditions and chronic pain. Treatments follow a three-phase model of Preparation, Discovery, and Integration, with on-site physicians, anesthesiologists, and psychiatrists administering care under Health Canada approvals.

Product overview

SABI Mind is a psychedelic-assisted therapy clinic offering ketamine and rTMS treatments across two Canadian locations (Calgary and Victoria, BC). The core offerings include SABI Therapy for Mental Health and Chronic Pain (using ketamine), and EXOMIND™ (using patented ExoTMS™ rTMS technology). The company provides a three-phase healing approach: Preparation, Discovery, and Integration. Additional services include SABI Somatics (body-centered therapies), counselling, and manual therapy. Beyond The Call is a specialized sub-brand offering mental health services for first responders with reduced pricing. The company also conducts clinical research including psilocybin trials and maintains NHSF accreditation for IV ketamine administration.

Differentiator

Problem solved

Functional benefit

Brands

  • EXOMIND: A groundbreaking mental wellness therapy using patented ExoTMS technology for repetitive transcranial magnetic stimulation (rTMS) to treat symptoms of depression and improve mental health.
  • SABI Therapy for Chronic Pain (STCP)
  • Beyond The Call
  • SABI Somatics
  • EXOMIND Support Initiative

Products and services

  • SABI Therapy for Mental Health Ketamine-assisted psychotherapy administered intramuscularly by qualified physicians, combined with preparation, discovery, and integration phases for individuals with treatment-resistant depression, PTSD, anxiety, and related mental health conditions.
  • SABI Therapy for Chronic Pain (STCP) Interdisciplinary chronic pain program led by chronic pain specialists, using ketamine-assisted therapy combined with integrative therapies for chronic pain conditions.
  • EXOMIND™ Non-invasive, drug-free neuromodulation therapy using patented ExoTMS™ repetitive transcranial magnetic stimulation (rTMS) technology, Health Canada-cleared for the treatment of depression.
  • Beyond The Call Dedicated mental health platform for first responders (police, firefighters, paramedics) offering EXOMIND therapy, ketamine therapy, and counselling services with reduced pricing and the EXOMIND Support Initiative providing fully covered treatments for eligible first responders.
  • SABI Somatics Body-centered mental health service stream offering osteopathic manual therapy, somatic therapy, and somatic experiencing coaching for trauma and nervous system regulation.
  • Intravenous (IV) Ketamine Therapy Intravenous ketamine therapy for treatment-resistant mental health conditions and chronic pain, enabled by provisional Non-Hospital Surgical Facility (NHSF) accreditation from the College of Physicians and Surgeons of Alberta.
  • PsilWell Wellness-Focused Psilocybin Therapy Trial Wellness-focused psilocybin therapy clinical trial program offering screening, psilocybin-assisted group therapy, and follow-up care for adults aged 18-65, operated in Victoria under Health Canada authorization.
  • Equitable Access Program (EAP) Access program providing chronic pain and mental health care to historically underserved, underrepresented, or low-income patient populations at reduced or subsidized pricing.
  • Psychedelic-Assisted Therapy (PAT) Therapeutic technique using psychedelic substances administered in low to moderate doses under supervision of trained medical and mental health professionals, available at the Victoria location.
  • Therapy & Counselling Evidence-based therapeutic approaches tailored to individual client needs for anxiety, depression, relationship issues, and life transitions, delivered as part of the Preparation and Integration phases.
  • Manual Therapy Hands-on manual therapy techniques including osteopathy to manipulate and mobilize muscles and joints, alleviate pain, enhance mobility, and release trauma stored in the body.

Quantifiable outcome

  • PsilWell clinical trial: CAD 4,500 per participant program

Companies that use SABI Mind

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

SABI Mind technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

SABI Mind partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • Optimi HealthcoreTechnology or Integration · 1 June 2022Supply partnership for psilocybin and MDMA therapeutic substances used in clinical trials and treatment programs. Optimi Health provides naturally-sourced psychedelic compounds for therapeutic applications.
  • Filament Health Corp.coreTechnology or Integration · 1 June 2022Psilocybin supply agreement ensuring availability of pharmaceutical-grade psilocybin for clinical research and patient treatment programs.
  • PharmAla BiotechcoreTechnology or Integration · 1 May 2022MDMA supply agreement providing pharmaceutical-grade MDMA for clinical research and therapeutic applications. PharmAla Biotech is a Canadian company specializing in psychoactive compound manufacturing for clinical use.
  • Reverie PsychedeliccoreStrategic or Co-development Partner · 1 March 2022Research partnership focused on advancing psychedelic-assisted therapy protocols and clinical research initiatives for mental health treatments.
  • TheraPsilcoreStrategic or Co-development PartnerPartnership supporting the PsilWell clinical trial, involving collaboration on psilocybin-assisted therapy research for treatment-resistant conditions.
  • Beyond The CallflagshipGTM or Marketing PartnerEXOMIND Support Initiative partnership providing specialized mental health programs for first responders including police, firefighters, and paramedics, with 20% discounted pricing on programs.

Scale indicators2 records

Recent moves9 records

Expansion highlights6 records

SABI Mind competitors and assessment

Company assessment

Direct peers

  • Field Trip Health & Wellness: Field Trip Health & Wellness operates psychedelic-assisted therapy clinics across Canada and the US, directly competing with SABI Mind in ketamine and psilocybin-based mental-health treatment in the same patient segment.
  • Numinus Wellness: Numinus runs ketamine-assisted therapy clinics in Canada (including British Columbia) and operates a psychedelic research division, overlapping directly with SABI Mind on clinic-based psychedelic therapy in Western Canada.
  • ATMA Journey Centers: ATMA operates psychedelic-assisted therapy clinics in Western Canada focused on personal-growth and mental-health programs, competing for the same treatment-resistant patient base as SABI Mind's Calgary and Victoria clinics.

Emerging players

  • TheraPsil: TheraPsil is a Canadian non-profit that runs psilocybin-assisted therapy programs and is an active research partner of SABI Mind (PsilWell trial); its clinical and training activities overlap with SABI Mind's psychedelic therapy offerings.
  • Clairvoyant Therapeutics: Clairvoyant Therapeutics is a Canadian clinical-stage psychedelic company running psilocybin trials for alcohol use disorder, of which SABI Mind is the first Alberta clinical site — making it an immediate sponsor/customer peer.
  • Revive Therapeutics: Revive Therapeutics is a Canadian specialty psychedelics company focused on psilocybin therapeutics, positioning it as an adjacent player in the same psilocybin clinical-research ecosystem in which SABI Mind participates.
  • Mycotopia Therapies: Mycotopia Therapies provides psilocybin-based mental-health treatment programs in partnership with Canadian clinics; it competes for the same niche Canadian psilocybin-assisted therapy market as SABI Mind.

Broad incumbents

  • MindMed: MindMed is a publicly-traded psychedelic-medicine developer with clinical programs in mental health and a broader, drug-development-focused footprint than SABI Mind's clinical-services business — overlapping at the patient/indication level.
  • BrainsWay: BrainsWay manufactures FDA-cleared deep TMS systems used for depression and OCD treatment; SABI Mind's ExoTMS™/ExoMind™ TMS offerings compete for the same clinical indication and provider-customer relationships.
  • Cerebral: Cerebral is a large US digital mental-health provider offering telehealth therapy and medication management — a much broader, incumbent mental-health-services operator competing for the same downstream treatment-resistant depression patient demand that SABI Mind addresses.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

SABI Mind social profiles

Digital presence

SABI Mind compliance and trust

Trust signal

Compliance5 records

SABI Mind financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SABI Mind leadership team

Management profile

Number of profiles

Profiles7 records

SABI Mind funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SABI Mind M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SABI Mind

What does SABI Mind do?

SABI Mind operates clinical healing centres in Calgary and Victoria, BC, delivering ketamine-assisted psychotherapy, psilocybin-assisted therapy, MDMA-assisted therapy, and ExoMind™ repetitive transcranial magnetic stimulation (rTMS) to patients with treatment-resistant mental health conditions and chronic pain. Treatments follow a three-phase model of Preparation, Discovery, and Integration, with on-site physicians, anesthesiologists, and psychiatrists administering care under Health Canada approvals.

Is SABI Mind a public or private company?

SABI Mind is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was SABI Mind founded?

SABI Mind was founded in 2022. It employs 11 to 50 people.

Where is SABI Mind based?

SABI Mind is headquartered in Calgary, Canada, in the North America region.

How does SABI Mind make money?

Three revenue lines are on record. Therapeutic Treatment Services are the primary driver. The others are clinical Research Services and EXOMIND Support Programs.

Who are SABI Mind's main competitors?

Direct peers on record are Field Trip Health & Wellness, Numinus Wellness and ATMA Journey Centers. Emerging players are TheraPsil, Clairvoyant Therapeutics, Revive Therapeutics and Mycotopia Therapies. Broad incumbents are MindMed, BrainsWay and Cerebral.

Does SABI Mind have an API?

No public API is recorded for SABI Mind.

What industry is SABI Mind in?

SABI Mind's product category is Mental Health & Chronic Pain Treatment Services. Its primary akta.pro industry code is HLAFABAC, Outpatient Mental Health & Counseling Clinics, with a secondary code of HLADAJAG, Multidisciplinary Outpatient Rehab Centers (PT/OT/SLP). Its NAICS code is 621420 and its SIC code is 8093.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DSABI Mind Inc., a corporation incorporated in Alberta, Canada, filed a Form D with the U.S. Securities and Exchange Commission for an exempt offering of equity securities under Rule 506(b). The filing discloses that $180,365 USD was raised from five investors, with no sales commissions or finder's fees incurred. This regulatory submission serves as a notice of the completed private placement activity.GlobeNewswireOptimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMAOptimi Health signed a supply agreement with SABI Mind to provide GMP psilocybin and MDMA for psychedelic-assisted therapies. The supplies are pending Health Canada licensing amendment approval and will be used for approved patients, clinical trials, and academic studies.NewswirePharmAla Biotech & SABI Mind Announce MDMA Supply AgreementPharmAla Biotech signed an agreement with SABI Mind to supply GMP MDMA for use at SABI Mind's Healing Centres in Calgary, Edmonton, and Victoria, subject to Health Canada approval. The MDMA will come from PharmAla's North American cGMP value chain, and PharmAla will have access to anonymized patient data.SecSEC FORM DSABI Mind Inc., a corporation incorporated in Alberta, Canada, filed a Form D with the U.S. Securities and Exchange Commission for an exempt offering of securities under Rule 506(b). The filing discloses a total offering amount of $1,549,230 USD, with $154,716 USD already sold to four investors as of December 21, 2021. This regulatory submission serves as a formal notice of the private placement to relevant authorities.